Psychiatr. pro Praxi, 2001; 2: 62-66

Zásady dlouhodobé léčby deprese

MUDr. Michal Maršálek CSc
Psychiatrická léčebna Bohnice, Praha

Keywords: long-term treatment of depression, unipolar depression, bipolar affective disorder, antidepressants, thymoprophylactics, psychotherapy, placebo responders.

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Maršálek M. Zásady dlouhodobé léčby deprese. Psychiatr. praxi. 2001;2(2):62-66.

Význam dlouhodobé léčby deprese v posledních letech roste, protože se prokázalo, že opakování depresivních fází zhoršuje prognózu onemocnění. Po odeznění akutních příznaků se rozlišuje pokračovací a udržovací léčba. V obou fázích zůstává dávka antidepresiva stejná jako při akutní léčbě. Podskupina depresivních pacientů se může zlepšit na placebu v akutní fázi léčby, tento efekt však nepřetrvává při pokračovací léčbě. Postup při dlouhodobé léčbě se liší podle typu deprese. U bipolární afektivní poruchy jsou lékem volby thymoleptika a antidepresiva jsou nevhodná. U unipolární deprese je stejně účinné lithium i antidepresiva. Díky malému výskytu nežádoucích účinků mají přednost antidepresiva 3. a 4. generace před ostatními antidepresivy i před lithiem. Význam psychoterapie v dlouhodobé léčbě deprese není dostatečně prozkoumaný. Zdá se, že se uplatňuje především u lehkých depresí s normálním EEG záznamem pomalovlnného spánku.

Principles of long-term treatment of depression

The significance of long-term treatment of depression has been rising in the past years, as it became known that repeated depressive phases aggravate the prognosis of the disease. Normally, once the acute symptoms have receded, a distinction is made between continuing treatment and maintenance treatment; but in both phases the dosage of antidepressants remains the same as for acute treatment. A subgroup of depressive patients may achieve progress by taking a placebo in the acute phase of the treatment; however this effect is not persistent during maintenance treatment. In long-term therapy, however, the approach varies depending on the type of depression. With bipolar affective disorders, thymoleptics are the treatment of choice and antidepressants are inappropriate. With unipolar disorders lithium and antidepressants are equally effective. Because of the low incidence of their side effects, third-and fourth-generation antidepressants are given priority over other antidepressants and lithium. The significance of psychotherapy in the long-term treatment of depression has not been sufficiently studied. It seems to be applicable chiefly to slight depressions with a normal slow-wave sleep EEG.

Download citation

References

  1. Angst J, Baastrup P, Grof P, et al.: The course of monopolar depression and bipolar psychosis. Psychiat Neurol Neurochir 1973, 76, 489-500.
  2. Anton SF, Robinson DS, Roberts DL, et al: Long-term treatment of depression with nefazodone. Psychopharmacol Bull 1994, 30, 165-169. Go to PubMed...
  3. Baldessarini RJ, Tonto L, Faedda GL, et al: Effcts of the rate of discontinuatuing lithium maintenance treatment in bipolar disorders. J Clin Psychiat 1996, 57, 441-448. Go to original source... Go to PubMed...
  4. Bremner JD, Smith WT: Org 3770 vs amitriptyline in the contiunation treatment of depression: a placebo controlled trial. Eur J Psychiat 1996, 10, 5-15.
  5. Coopen A, Ghose K, Montgomery SA, et al: Continuation therapy with amitriptyline in depression. Br J Psychiat 1978, 133, 28-33. Go to original source... Go to PubMed...
  6. Calabrese JR, Woyshville MJ: A medication algorithm for treatment of bipolar rapid cycling?. J Clin Psychiat 1995, 56 (suppl 3), 11-18.
  7. Češková E: Úskalí dlouhodobé antidepresivní léčby. ČS Psychiat 2000, 96, 244-247.
  8. Dalery J, Dagens-Lafant V, de Bodinat C: Value of tianeptine in treating major recurrent unipolar depression. Study versus placebo for 16 1/2 months of treatment. Encephale 1997, 23, 56-64. Go to PubMed...
  9. Doogan DP, Caillard V: Sertraline in the prevention of depression. Br J Psychiat 1992, 160, 217-222. Go to original source... Go to PubMed...
  10. Entsuah AR, Rudolph RL, Hackett D, Miska S: Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol 1996, 11, 137-145. Go to original source... Go to PubMed...
  11. Frank E, Kupfer DJ, Perel JM, et al: Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiat 1990, 47, 1093-1099. Go to original source... Go to PubMed...
  12. Frank E, Kupfer DJ, Perel JM, et al: Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 1993, 27, 139-145. Go to original source... Go to PubMed...
  13. Georgotas A, McCue RE, Cooper TB: A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiat 1989, 46, 783-786. Go to original source... Go to PubMed...
  14. Greil W, Ludwig-Mayerhofer W, Steller B, et al: Lithium - oder Carbamazepinprophylaxe bei affektiven Psychosen? Ergebnisse einer kontrollieren, multizentrischen Studie. In: Müller - Oerlinghausen B, Berghöfer A, (eds): Ziele und Ergebnisse der medikamentösen Prophylaxe affektiven Psychosen. Georg Thieme Verlag, Stuttgart 1994, 113-119.
  15. Goodwin FK, Jamison KR: Course and oucome. In: Goodwin FK, Jamison KR (eds): Manic-depressive illness. Oxford University Press, New York 1990, 127-156.
  16. Jacoby R, Lunn MA, Ardern M, et al: How long should the elderly také antidepressants? A double-blind placebo-controlled study of continuation/prophylaxis therapy with dothiepin. Br J Psychiat 1993, 162, 175-182. Go to original source...
  17. Kasper S: Long-term treatment of depression with antidepressants: Evidence from clinical trials, prediction and practical guidelines. In: Honig A, van Praag HM (eds): Depression: Neurobiological, psychopathological and therapeutic advances. 1st edn. Wiley and Sons Ltd, New York 1997, 499-518.
  18. Keller MB: The long-term treatment of depression. J Clin Psychiat 1999, 60 (suppl. 17), 41-45.
  19. Keller MB, Shapiro RW: Double depression: Superimposition of acute depressive episodes on chronic depressive disorders. Am J Psychiat 1982, 139, 438-442. Go to original source... Go to PubMed...
  20. Keller MB, Kocsis JH, Thase ME, et al.: Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998, 280, 1665-1672. Go to original source... Go to PubMed...
  21. Klerman GL, DiMascio A, Weissman M, Prusoff B, Paykel ES: Treatment of depression by drugs and psychotherapy. Am J Psychiat 1974, 131, 186-191. Go to original source... Go to PubMed...
  22. Kocsis JH, Friedman RA, Markowitz JC, et al.: Maintenance therapy for chronic depression. A controlled clinical trial of desipramine. Arch Gen Psychiat 1996, 53, 769-774. Go to original source... Go to PubMed...
  23. Kupfer DJ, Frank E, McEachran, et al: Delta sleep ratio: a biological correlate of early recurrence in unipolar disorder. Arch Gen Psychiat 1990, 47, 1100-1105. Go to original source... Go to PubMed...
  24. Kupfer DJ, Frank E, Perel JM, et al: Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiat 1992, 49, 769-773. Go to original source... Go to PubMed...
  25. Lavori PW, Keller MB, Scheftner W, et al: Recurrence after recovery in unipolar MDD: an observational follow-up study of clinical predictors and somatic treatment as a mediating factor. Int J Methods Psychiat 1994, 211-229.
  26. Malt UF: Practical aspects of long-term treatment. Eur Neuropsychopharmacol 1995, 5, 288. Go to original source...
  27. Mindham RHS, Howland C, Shepherd M: An evaluation of continuation therapy with tricyclic antidepressants in depressive illnesses. Psychol Med 1973, 3, 5-17. Go to original source... Go to PubMed...
  28. Montgomery SA: Long-term treatment of depression. Br J Psychiat 1994, 165 (suppl 26), 31-36. Go to original source...
  29. Montgomery SA, Cassano GB: Management of bipolar disorder. Martin Dunitz Ltd, 1st edn, London 1996.
  30. Montgomery SA, Dunbar GC: Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993, 8, 198-195. Go to original source... Go to PubMed...
  31. Montgomery SA, Dufour H, Brion S: The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiat 1988, 153 (suppl 3), 69-76. Go to original source...
  32. Montgomery SA, Rasmussen JGC, Tanghoj P: A 24 week study of 20 mg citalopram, 40 mg citalopram and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993, 8, 181-188. Go to original source... Go to PubMed...
  33. Montgomery SA, Reimitz PE, Zivkov M: Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998, 13, 63-73. Go to original source... Go to PubMed...
  34. NIMH consensus development conference statement. Mood disorders: Pharmacologic prevention of recurrences. Am J Psychiat 1985, 142, 469-476.
  35. Post RM, Leverich GS, Altshuler L, Mikalauskas K: Lithium discontinuation-induced refractoriness: preliminary observations. Am J Psychiat 1992, 149, 1727-1729. Go to original source... Go to PubMed...
  36. Prien RF, Kupfer DJ: Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiat 1986, 143, 18-23. Go to original source... Go to PubMed...
  37. Prien RF, Kocsis JH: Long-term treatment of mood disorders. In: Bloo FE, Kupfer DJ, (eds. Psychopharmacology: The fourth generation of progress, Raven Press, New York 1995, 1067-1079.




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.